Mark Lythgoe
Apr 14, 2025, 11:06
Mark Lythgoe: Do we need to re-evaluate the clinical utility of how we measure PDL1?
Mark Lythgoe, Clinical Research Fellow in Medical Oncology at Imperial College London, shared a post on X:
“Not all PDL1 assays are the same in bladder cancer – important work. do we need to re-evaluate the clinical utility of how we measure PDL1 and does this have implications for other cancers???”
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Authors: Matthew D. Galsky et al.
Aristotelis Bamias
cancer
Deepali Rishipathak
Eiji Kikuchi
Enrique Grande
Hartmut Koeppen
Ian D. Davis
Ira Mellman
Jonathan F. Anker
Jose Angel Arranz
Juliette Roels
Justin M. David
Kobe Yuen
Maria De Santis
Mark Kockx
Mark Lythgoe
Matthew D. Galsky
Maureen Peterson
OncoDaily
Oncology
Patrick Williams
Robert J. Johnston
Romain Banchereau
Roos Van Elzen
Sacha Gnjatic
Sandrine Bernhard
Sanjeev Mariathasan
Saurabh Gupta
Shomyseh Sanjabi
Sudeh Izadmehr
Xiangnan Guan
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11